CeloNova BioSciences’s Coronary Stent System Could Mean Faster Healing Of Arteries And Greatly Reduced Use Of Blood-Thinning Medication

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN ANTONIO--(BUSINESS WIRE)--CeloNova BioSciences, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted approval to start an investigative device exemption (IDE) trial for its novel coronary stent system – the Cobra PzF™ coronary stent system. Coronary stents are thin wire mesh devices used in minimally invasive heart surgery to prop open clogged blood vessels of the heart.

Help employers find you! Check out all the jobs and post your resume.

Back to news